News Release

Cleanascite™ Sample Prep Improves Nanopore Detection of microRNA from Saliva

MONMOUTH JUNCTION, NJ, August 26, 2024 -- Biotech Support Group reports on a journal article describing the simplicity and efficiency of using Cleanascite™ to eliminate interferences from lipids and lipoproteins that nonspecifically interact with a nanopore channel.

The citation is:

Arora, Pearl, et al. "Nanopore‐based detection of periodontitis biomarker miR31 in saliva samples." Electrophoresis (2024).

Aberrations in the microRNAs (miRNA) levels have been the cause behind various diseases, including periodontitis. Therefore, sensitive, specific, and accurate detection of disease-associated miRNAs is vital to early diagnosis and can facilitate inhibitor screening and drug design. In this study, the researchers developed a label-free, real-time sensing method for the detection of miR31, which has been frequently linked to periodontitis, using an engineered protein nanopore and in the presence of a complementary ssDNA as a molecular probe. When human saliva was tested however, extended pore blockage with large noise levels was noted due to the presence of interfering lipid or lipoprotein complexes. To circumvent this, the article states “we found that that the nonspecific pore blockage by the sample matrix could be significantly diminished by simply treating human saliva samples with Cleanascite. …By taking advantage of Cleanascite treatment, the saliva samples produced current modulations with similar signatures to that of the miR31-p5 duplex in the control (i.e., in water solutions).” The authors conclude that their method is rapid and highly sensitive with nanomolar concentration of miR31 that could be determined in minutes. In addition, artificial saliva and human saliva samples were successfully analyzed. The developed nanopore sensing platform could be used to detect other miRNAs and offers a potential application for the clinical diagnosis of disease biomarkers.

“I am pleased to see that this is the second reported use of Cleanascite™ for removing interferences from lipids and lipoproteins in nanopore analysis. Its simplicity in use and lipid removal efficiency should extend to eventual clinical analysis of disease biomarkers from saliva.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information visit: Cleanascite™ Lipid Removal Reagent and Clarification, at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm

Keywords: Cleanascite™, lipid interference, Saliva biomarkers, microRNA analysis, nanopore analysis

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for expanding proteomic analysis. Following a tiered business strategy, the company continues its growth in the consumable research products area. For this market, key products include: AlbuVoid™ and AlbuSorb™ PLUS for albumin & IgG depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NRicher™ for low abundance and family specific proteome enrichment. For more information, go to http://www.biotechsupportgroup.com

For business development contact: Matthew Kuruc
732-274-2866 mkuruc@biotechsupportgroup.com